III

BitNile Metaverse Regains Compliance with the Nasdaq Voting Rights Rule

Retrieved on: 
Tuesday, October 17, 2023
Electronic Games, Technology, Entertainment, Fintech, Online, Professional Services, General Entertainment, Internet, Cryptocurrency, III, Venture round, Certificate, Security (finance), Metaverse

BitNile Metaverse, Inc. (Nasdaq: BNMV) (“BitNile Metaverse” or the “Company”), announced today that it has regained compliance with the Nasdaq Voting Rights Rule.

Key Points: 
  • BitNile Metaverse, Inc. (Nasdaq: BNMV) (“BitNile Metaverse” or the “Company”), announced today that it has regained compliance with the Nasdaq Voting Rights Rule.
  • On June 21, 2023, the Nasdaq Stock Market (“Nasdaq”) notified the Company that the issuance of the Series B and Series C Preferred Stock violated Nasdaq’s voting rights rule under listing Rule 5640 (the “Voting Rights Rule”).
  • As a result, the Company has regained compliance with the Voting Rights Rule.
  • “We are pleased to regain compliance with Nasdaq’s Voting Rights Rule and look forward to a continued healthy relationship with the exchange.

St. Thomas University Mourns the Passing of Miami Gardens Mayor Shirley Gibson

Retrieved on: 
Tuesday, October 17, 2023
III, Partnership, Park, Jazz in the Park, University, STU, City, Commissioner, County commission, Gibson, Growth, Santa Clara University School of Education, Counseling Psychology, and Pastoral Ministries, MIAMI, Friends, St. Thomas University, Drug

MIAMI GARDENS, Fla., Oct. 17, 2023 /PRNewswire/ -- St. Thomas University (STU) joins the residents and friends of the City of Miami Gardens in mourning the passing of Mayor Shirley Gibson.

Key Points: 
  • MIAMI GARDENS, Fla., Oct. 17, 2023 /PRNewswire/ -- St. Thomas University (STU) joins the residents and friends of the City of Miami Gardens in mourning the passing of Mayor Shirley Gibson.
  • Mayor Gibson was instrumental in the 2003 establishment of Miami Gardens as a city, and its first mayor, serving for two terms.
  • She played a key role in the connection between the City of Miami Gardens and St. Thomas University.
  • We pray that Mayor Shirley Gibson's life continues to inspire generations of leaders and citizens in the City of Miami Gardens.

Streamline Health® Executes Strategic Restructuring, Provides Corporate Update

Retrieved on: 
Monday, October 16, 2023
III, Health, MBA, Interest, Lockwood, Greene & Co., Agilysys, Computation, Certified Public Accountant, DePauw University, Software as a service, McKesson Corporation, Sonia Revid, Bryant, BMO Capital Markets, Interim, Workforce, Growth, Accounting, Streamline, Executive, Attention, Clemson University, Villanova University, Management, Economics

The strategic restructuring initiatives are designed to reduce expenses and preserve cash while maintaining the Company’s ability to expand its high-margin SaaS business.

Key Points: 
  • The strategic restructuring initiatives are designed to reduce expenses and preserve cash while maintaining the Company’s ability to expand its high-margin SaaS business.
  • As part of the strategic restructuring initiatives, the Company has implemented a reduction in force of approximately 26 employees (approximately 24% of its workforce).
  • The Company expects the expense associated with the strategic restructuring to be substantially recognized by the end of fiscal 2023.
  • As a result of these strategic restructuring initiatives, the Company expects to realize annualized cost savings of approximately $5.8 million.

Jonathan Milner Issues Statement Responding to ISS Report

Retrieved on: 
Monday, October 16, 2023
MAKE, ACT, III, AWARE, NO, AMERICA, NOT, PAST, TIME, DATE, THIS, AS, NORTH, USE, ANY, OF, IT, FOR, UPON, FINANCIAL, FCA, ITS, SET, IS, TAX, EXPRESS, EUROPEAN UNION, ALL, FAIR, UPDATE, BY, FUTURE, EACH, AND, Glass fiber, Medical device, Audit, EU

T: +44 7733 265 198 / E: [email protected]

Key Points: 
  • T: +44 7733 265 198 / E: [email protected]
    T: +44 (0)20 3709 5700 / E: [email protected]
    T: +1 646 677 1811 / E: [email protected]
    THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company

Retrieved on: 
Monday, October 16, 2023
ACT, MAKE, III, AWARE, NO, AMERICA, NOT, PAST, TIME, DATE, THIS, AS, NORTH, USE, ANY, OF, IT, FOR, UPON, PER, FINANCIAL, FCA, ITS, SET, IS, TAX, EXPRESS, EUROPEAN UNION, ALL, FAIR, UPDATE, BY, FUTURE, EACH, AND, Glass fiber, Medical device, Audit, EU

DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.

Key Points: 
  • DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
  • DR. MILNER IS NOT RESPONSIBLE TO ANY PERSON FOR PROVIDING ADVICE IN RELATION TO THE SUBJECT MATTER OF THIS DOCUMENT.
  • DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

Retrieved on: 
Sunday, October 15, 2023
III, PPT, Pain, Professor, Hidradenitis, Quality of life, European Academies' Science Advisory Council, Pharmacokinetics, Doctor of Philosophy, MS, Journal of the European Academy of Dermatology and Venereology, Education, DLQI, Data, Venereology, Safety, Psoriasis, Hidradenitis suppurativa, Moonlake, Disease, FDA, Adalimumab, Webcast, Immunology, Maintenance, Abscess, I&I, Master of Education, MIRA, PGI, Pennsylvania State University, Patient, HS, Pharmaceutical industry, Perfume, Birth control, Dermatology, MD, Inflammation

We have consistently observed best-in-class clinical activity with our Nanobody®sonelokimab for hidradenitis suppurativa and these results demonstrate its effect on a number of clinically meaningful endpoints.

Key Points: 
  • We have consistently observed best-in-class clinical activity with our Nanobody®sonelokimab for hidradenitis suppurativa and these results demonstrate its effect on a number of clinically meaningful endpoints.
  • In June we elevated the bar for clinical response to HiSCR75 as the primary endpoint.
  • The MIRA trial set a landmark milestone as the first placebo-controlled randomized trial in HS to use Hidradenitis Suppurative Clinical Response 75 (HiSCR75) as the primary endpoint.
  • The 24-week results show that ongoing treatment with sonelokimab 120mg and 240mg dosed Q4W, further increased HiSCR75 response rates compared to week 12.

Barrick Set for Strong Finish to the Year

Retrieved on: 
Thursday, October 12, 2023
Terrorism, Public expenditure, Engineering, Framework agreement, Gold, Weather, COVID-19, Master of Philosophy, WGC, News, Copper, Water, Mining, Government, Economics, Insurance, BNL, Resource, The central science, Health, Climate change, Risk, Epidemic, Electricity, Natural gas, Framework, Pandemic, Shareholder, World Gold Council, Accident, Nationalization, Mineral Resources Limited, Investment, Partnership, Papua New Guinea, Local-level governments of Papua New Guinea, Nevada Gold Mines, Depreciation, National instrument, III, Silver, MD, Loss, Failure, Corruption, Maintenance, Mineral, PNG, Real estate, Security (finance), Veladero, Kibali Gold Mine, Lead

TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) today reported preliminary Q3 sales of 1.03 million ounces of gold and 101 million pounds of copper, as well as preliminary Q3 production of 1.04 million ounces of gold and 112 million pounds of copper. Q3 production was higher than Q2, although lower than previous plans for the quarter, especially at Pueblo Viejo where equipment design deficiencies contributed to the delayed ramp up of the expansion project. We continue to expect a significant increase in fourth quarter production volume.

Key Points: 
  • Porgera has been on temporary care and maintenance since April 2020 and is not currently included in our full year 2023 guidance.
  • On February 3, 2022, the Framework Agreement was replaced by the more detailed Porgera Project Commencement Agreement (the “Commencement Agreement”).
  • Barrick will provide a full reconciliation of these non-GAAP financial measures when the Company reports its quarterly results on November 2, 2023.
  • Barrick also cautions that its 2023 guidance may be impacted by the ongoing business and social disruption caused by the spread of Covid-19.

Vistant Selected To Support Defense Health Agency’s National Capital Region Logistics Program

Retrieved on: 
Thursday, October 12, 2023
III, Army, Health, DHA, Walter Reed, Department of Defense Serum Repository, Navy, Government, NCR, Coast guard, Information, Safety, Walter Reed National Military Medical Center, Defense Health Agency, United States Public Health Service, Paralegal, Air force, Fort Belvoir, U.S. Army Acquisition Support Center, Telecommunications, Nursing, Defense

Vistant will provide program management support for DHA’s National Capital Region (NCR) Medical Directorate Logistics & Acquisition Support Program.

Key Points: 
  • Vistant will provide program management support for DHA’s National Capital Region (NCR) Medical Directorate Logistics & Acquisition Support Program.
  • Under this two-year, $3.7 million project, Vistant will staff, manage, and operate logistics for the NCR from the Walter Reed National Military Medical Center annex.
  • Earlier this year, Vistant was awarded a contract to provide operational support through DHA’s Clinical Operations Program Management Office.
  • Vistant paralegal experts now support active duty and retired service members of the Army, Navy, Air Force, Marines, Coast Guard, Public Health Service, and their dependents, as well as civilian employees of the Department of Defense.

Guerbet: CHMP positive opinion

Retrieved on: 
Thursday, October 12, 2023
III, European, European Commission, Committee for Medicinal Products for Human Use, CHMP, Radiology, Agent handling, Brain, Breast, Pancreas, Medicine, Central nervous system, Liver, Magnetic resonance imaging, European Medicines Agency, Spine, EMA, FDA, Kidney, Committee, Lung, Human, MRI, Tissue, Civil service commission, CNS, Prostate, Gadolinium, Patient, Regulatory affairs, Medical imaging, Health, EU

Approved by the FDA in September 2022, Elucirem™ is produced in France and in the USA.

Key Points: 
  • Approved by the FDA in September 2022, Elucirem™ is produced in France and in the USA.
  • Villepinte, France, 12 october 2023: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion concerning the granting of a marketing authorisation for Elucirem™ (Gadopiclenol) in the European Union (EU) for use in adults and children aged 2 years and over for MRI with contrast enhancement.
  • The positive opinion from the CHMP is essentially based on data from two phase III clinical trials completed in March 2021.
  • "This positive opinion from the CHMP,
    at the end of 2023, will bring European patients and health professionals

Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction

Retrieved on: 
Wednesday, October 11, 2023
Slate, Canadian House of Commons Special Committee on Electoral Reform, LLP, King & Wood Mallesons, Skadden, Arps, Slate, Meagher & Flom, Consortium, Schedule, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, US, Wardwell, Form 6-K, Tripura Merger Agreement, CICC, Person, Neal, Sub, Latham & Watkins, Proxy, Committee, Limited partnership, GTH, III, ODI, ADS, CCB, AND, Holding company, Security (finance), Auction, PRC, Parent, Share (finance), Mergers and acquisitions

BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), a wholly-owned subsidiary of Parent.

Key Points: 
  • BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), a wholly-owned subsidiary of Parent.
  • The Board, acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the “Special Committee”), approved the Merger Agreement and the Merger and resolved to recommend the Company’s shareholders vote to authorize and approve the Merger Agreement and the Merger.
  • The Special Committee negotiated the terms of the Merger Agreement with the assistance of its financial and legal advisors.
  • In connection with the Merger, the Company will prepare and mail to its shareholders a proxy statement that will include a copy of the Merger Agreement.